$2.84—Stale · unknown old
NASDAQ • Last print unknown ago
$2.84—Stale · unknown old
9/28/26
IM Cannabis (IMCC)
Monday
7:39 AM
ThesisRecent strategic partnerships and product launches are expected to enhance revenue growth and improve market sentiment towards IM Cannabis.
Revenue Outlook
The Bull Case for Growth
- 01IM Cannabis has secured a new distribution agreement with a major European pharmacy chain, potentially increasing market access by 30%.
- 02The company is in the process of launching a new line of CBD-infused wellness products, expected to capture a growing segment of the consumer market.
- 03Recent changes in Canadian cannabis regulations are expected to favor larger producers, potentially improving IM Cannabis's competitive position.
- 04The company reported a 40.8% increase in EPS, indicating a potential turnaround in profitability despite ongoing operational challenges.
- 05Growing acceptance of cannabis for medical use
- 06Expansion of the European cannabis market
- 07Changes in regulatory frameworks affecting cannabis sales in Canada and Europe
- 08Market share growth in the medical cannabis segment
FY2025 Snapshot
- Revenue
- $55M
- Rev. Growth
- +1.3%
- Gross Margin
- 17.7%
- Op. Margin
- -21.2%
- Net Margin
- -20.7%
- Net Income
- $-11M
- NI Growth
- -6.9%
- EPS
- $-80.10
- 1Y Return
- -94.9%
IMCC Chart
My Notes
- "We are committed to expanding our market presence and product offerings to meet the growing demand for medical cannabis."
- Moat: IM Cannabis's proprietary cultivation techniques and established distribution channels provide a moderate level of competitive advantage.
- growth - Investors looking for exposure to the expanding cannabis market and potential for high returns.
- Higher interest rates could increase financing costs for expansion and operational needs…
- Watch on earnings: Canadian medical cannabis market growth rate, Average selling price per gram of cannabis, Regulatory changes in key markets.
One Sentence Summary:
The bull case: IM Cannabis is positioned for +14.7% growth on the back of im cannabis has secured a new distribution agreement with a major european pharmacy chain.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers